Clinical trial
Combination Daclizumab/Sirolimus Therapy For the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis
NCT00078689 is registered in ClinicalTrials.gov with National Eye Institute (NEI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combination Daclizumab/Sirolimus Therapy For the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis
- Lead sponsor
- National Eye Institute (NEI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 3, 2004
- Completion date
- July 18, 2008
- Enrollment
- 6
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.